CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis
NASDAQ:CDIO - Nasdaq - US14159C1036 - Common Stock - Currency: USD
Taking everything into account, CDIO scores 2 out of 10 in our fundamental rating. CDIO was compared to 560 industry peers in the Biotechnology industry. While CDIO seems to be doing ok healthwise, there are quite some concerns on its profitability. CDIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CDIO has reported negative net income.
CDIO had a negative operating cash flow in the past year.
CDIO had negative earnings in each of the past 5 years.
CDIO had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of CDIO (-47.67%) is comparable to the rest of the industry.
With a decent Return On Equity value of -51.46%, CDIO is doing good in the industry, outperforming 64.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.67% | ||
| ROE | -51.46% | ||
| ROIC | N/A |
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDIO has been increased compared to 1 year ago.
Compared to 1 year ago, CDIO has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.42, we must say that CDIO is in the distress zone and has some risk of bankruptcy.
CDIO has a Altman-Z score of 1.42. This is in the better half of the industry: CDIO outperforms 68.51% of its industry peers.
CDIO has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CDIO has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: CDIO outperforms 41.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.42 |
ROIC/WACCN/A
WACC9.73%
2.3 Liquidity
A Current Ratio of 19.49 indicates that CDIO has no problem at all paying its short term obligations.
The Current ratio of CDIO (19.49) is better than 93.06% of its industry peers.
A Quick Ratio of 19.49 indicates that CDIO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 19.49, CDIO belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.49 | ||
| Quick Ratio | 19.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 78.36% over the past year.
The Revenue for CDIO has decreased by -36.22% in the past year. This is quite bad
EPS 1Y (TTM)78.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.83%
Revenue 1Y (TTM)-36.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5800.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 2032.01% yearly.
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CDIO. In the last year negative earnings were reported.
Also next year CDIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CDIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CDIO (7/11/2025, 8:00:02 PM)
4.15
-0.14 (-3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.86%
Inst Owner Change0%
Ins Owners4.09%
Ins Owner Change0%
Market Cap7.22M
Analysts82.86
Price Target61.2 (1374.7%)
Short Float %N/A
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)65.41%
Min EPS beat(2)47.17%
Max EPS beat(2)83.66%
EPS beat(4)4
Avg EPS beat(4)54.63%
Min EPS beat(4)41.18%
Max EPS beat(4)83.66%
EPS beat(8)6
Avg EPS beat(8)17.12%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)831.37%
Min Revenue beat(2)-80.39%
Max Revenue beat(2)1743.14%
Revenue beat(4)1
Avg Revenue beat(4)368.94%
Min Revenue beat(4)-93.86%
Max Revenue beat(4)1743.14%
Revenue beat(8)1
Avg Revenue beat(8)140.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)0%
EPS NY rev (3m)-2900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 362.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.63 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.87
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.18
FCFYN/A
OCF(TTM)-2.97
OCFYN/A
SpS0.01
BVpS6.54
TBVpS6.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.67% | ||
| ROE | -51.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 102.22% | ||
| Cap/Sales | 1918.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.49 | ||
| Quick Ratio | 19.49 | ||
| Altman-Z | 1.42 |
F-Score5
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)419.33%
Cap/Depr(5y)421.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.83%
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-36.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5800.82%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.22%
OCF growth 3YN/A
OCF growth 5YN/A